SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Sarepta Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$17.73+0.63 (+3.68%)
Close on Oct 19, 2026
- Market cap
- $1.87B
- P/E (TTM)
- –
- Dividend yield
- –
Sarepta Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Sarepta Therapeutics | Industry median |
|---|---|---|
| Market Cap | $1.87B | $197.05M |
| Enterprise Value | $1.08B | $106.56M |
| PS Ratio | 0.95 | 3.93 |
| PB Ratio | 1.23 | 2.14 |
| P/TBV Ratio | 1.25 | 2.46 |
| P/FCF Ratio | 22.88 | 18.25 |
| P/OCF Ratio | 16.87 | 13.78 |
Enterprise value
| Measure | Sarepta Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 0.55 | 2.69 |
| EV / FCF | 13.25 | 21.02 |
Income (trailing twelve months)
| Measure | Sarepta Therapeutics | Industry median |
|---|---|---|
| Revenue | $1.97B | $57.94M |
| Operating Income | -$143.25M | -$21.44M |
| Pretax Income | -$130.92M | -$14.45M |
| Net Income | -$136.73M | -$22.46M |
| EBITDA | -$98.54M | -$16.91M |
| EPS (Diluted) | -$1.60 | -$0.83 |
Margins
| Measure | Sarepta Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -7.26% | -44.5% |
| Pretax Margin | -6.63% | -13.0% |
| Profit Margin | -6.93% | -39.2% |
| EBITDA Margin | -4.99% | -31.3% |
| FCF Margin | 4.15% | -8.85% |
Returns
| Measure | Sarepta Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -9.32% | -53.1% |
| Return on Assets (ROA) | -3.98% | -41.0% |
| Return on Invested Capital (ROIC) | -16.8% | -32.0% |
| Return on Capital Employed (ROCE) | -5.33% | -37.8% |
Growth
| Measure | Sarepta Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -20.4% | 6.01% |
| Revenue Growth (3Y CAGR) | 33.1% | 2.25% |
| Revenue Growth (5Y CAGR) | 32.4% | 6.42% |
Balance sheet
| Measure | Sarepta Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $788.49M | $62.42M |
| Net Cash (Debt) | $788.49M | $15.68M |
| Net Cash Per Share | $7.46 | $0.65 |
| Equity (Book Value) | $1.53B | $48.79M |
| Book Value Per Share | $14.46 | $1.36 |
| Tangible Book Value | $1.50B | $23.06M |
| Working Capital | $1.72B | $75.77M |
Financial position
| Measure | Sarepta Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.42 | 3.30 |
| Quick Ratio | 2.32 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Sarepta Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | $111.01M | -$12.35M |
| Capital Expenditures | -$29.16M | -$1.06M |
| Free Cash Flow | $81.85M | -$20.28M |
| FCF Per Share | $0.77 | -$0.41 |
Efficiency
| Measure | Sarepta Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.57 | 0.38 |
| Revenue Per Employee | $2.36M | $398.96K |
| Profits Per Employee | -$163.74K | -$732.08K |
| Employee Count | 835 | 73 |
Dividends and yields
| Measure | Sarepta Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -7.30% | -21.2% |
| FCF Yield | 4.37% | -7.64% |
Shares
| Measure | Sarepta Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 105,627,000 | 59,128,900 |
| Shares Change (YoY) | -1.10% | 11.1% |
| Shares Change (QoQ) | 0.05% | 0.54% |
| Float | 99,420,200 | 48,744,500 |
| Shares Held by Insiders | 5.88% | 11.8% |
| Shares Held by Institutions | 102.3% | 59.4% |
Taxes
| Measure | Sarepta Therapeutics | Industry median |
|---|---|---|
| Income Tax | $5.81M | $91.50K |
Scores
| Measure | Sarepta Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -0.20 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Sarepta Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.